Scott Kelly and Mark Kelly are American astronauts and identical twin brothers. They participated in NASA's Twins Study, conducted between 2015 and 2018. Scott Kelly appeared on Fox News with ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous challenges plaguing the company resulted in the dilution of the stock ...

The deal is expected to close in the second quarter of 2025 pending approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. It is projected the acquisition will ...

Australian audiences are about to have their trivia skills put to the test with ABC set to premiere “Claire Hooper’s House of Games,” a new quiz show hosted by Australian comedian Claire Hooper.

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

Dr. Michael Hooper is vice president and chief academic officer at Sentara Health and a leader in clinical care and academic medicine. With a wealth of experience in pulmonology and critical care ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to jointly develop and commercialize an experimental heart disease ...

“I was a hooper. I wasn’t touching no football,” the NFL-bound defensive tackle, who had a predraft visit with the Green Bay Packers on Friday, according to a source, said at South Carolina ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...